LFG
BBIO icon

Larson Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Larson Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,500
Closed -$12K – 1712
2023
Q2 		$12K Buy
+2,500
New +$37.6K ﹤0.01% 878

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Larson Financial Group's BBIO Position: Q2 2026 in Review

Larson Financial Group reduced its BridgeBio Pharma (BBIO) stake by 0.71% in Q2 2026, selling an estimated $140 and leaving 278 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1994.

Larson Financial Group first reported a position in BBIO in Q3 2021 and has held it in 16 quarters since. The position peaked at $36.8K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Larson Financial Group held 278 shares of BridgeBio Pharma worth $20.7K as of Q2 2026.
  • Larson Financial Group sold 2 BridgeBio Pharma shares in Q2 2026, an estimated $140.
  • BridgeBio Pharma made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1994 holding.
  • Larson Financial Group first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 16 quarters since.
  • Larson Financial Group's BridgeBio Pharma position peaked at $36.8K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.